Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivani MedicalVANI -2.59%33 Earnings per Share (Diluted) is $-0.35 as of Jun. 2026. GuruFocus rates VANI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Vivani Medical ranks worse than 76.98% on this metric.
Vivani Medical's EPS (Basic) for the
three
months ended in Jun. 2026 was $-0.07.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.35.
During the past 3 years, the average EPS without NRIGrowth Rate was -6.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -8.20% per year.
During the past 6 years, Vivani Medical's highest 3-Year average EPS without NRI Growth Rate was -3.30% per year. The lowest was -21.30% per year. And the median was -6.10% per year.
Vivani Medical (NAS:VANI) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Vivani Medical Earnings per Share (Diluted) Related Terms
Vivani Medical Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Vivani Medical's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VANI vs BDTX, VTVT, TLSA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Vivani Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivani Medical PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivani Medical's PE Ratio distribution charts can be found below:
* The bar in red indicates where Vivani Medical's PE Ratio falls into.
Vivani Medical Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Vivani Medical's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.35 mean?
Vivani Medical (VANI) has a Earnings per Share (Diluted) of $-0.35 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Vivani Medical and its competitors. According to the industry distribution chart, Vivani Medical ranks #893 out of 1160 companies in the Biotechnology industry, placing it in the top 77%.
Is Vivani Medical's Earnings per Share (Diluted) too high?
Vivani Medical's current Earnings per Share (Diluted) is $-0.35. Based on the distribution chart, Vivani Medical ranks #893 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivani Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's Earnings per Share (Diluted) compare to BDTX and VTVT?
According to the Biotechnology industry distribution chart, Vivani Medical ranks #893 out of 1160 companies for Earnings per Share (Diluted). This places Vivani Medical in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Vivani Medical and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivani Medical's current Earnings per Share (Diluted) is $-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (VANI) has a current Earnings per Share (Diluted) of $-0.35. The current Earnings per Share (Diluted) is $-0.35. Vivani Medical's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Vivani Medical (VANI), the current Earnings per Share (Diluted) is $-0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
33GF Score
Get the complete analysis for VANI
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VANI has been successfully added to your 
